Next Phase Newsletter

A venture capital firm based in the US has a partner in China that can provide support to companies interested in China market entry, but companies do not need to have a China angle. The firm has great experience with working with regulatory agencies to gain product approval for both FDA and CFDA. Since its establishment, the firm has invested in over 60 companies and continues to actively seek life science investments with its latest fund, aiming to invest in 8-10 companies per year. The firm usually participates in seed to series B financing rounds with check sizes between $500K – 2M and will consider companies based in USA and China. 
 
The firm is opportunistic and will consider all early-stage opportunities in therapeutics, medical devices, diagnostics, and digital health, as long as the technology is considered highly disruptive. The firm’s greatest focus lies in the medical device sector in which the firm has the strongest expertise. In therapeutics, the firm will consider pre-clinical and phase I assets. In medical devices and diagnostics, the firm is open to all classes of medical devices including 510k and PMA that are in development or clinical trials. The firm has reviewed companies of various stages in the past: those that have just developed a valid prototype, and those that were already profitable prior to investment. 
 
The firm seeks to work with companies with an experienced management team, ideally led by a serial entrepreneur with a successful track record. The firm can both lead and co-invest but prefers to lead financing rounds for medical device companies and will most likely take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A Europe-based firm began as a support structure for an initial group of private investors interested in life sciences and grew into a platform that sources investment opportunities and represents several high net-worth individuals, as well as strategy partners. The firm’s network invests globally in biotherapeutic companies, primarily focusing on Seed to Series A stages, and expects to participate in a limited number of later stage investments, following the capital allocation desires of the private investor network. The firm’s investors typically invest as a group, with check sizes ranging from $1-3M USD with the intention to make up to 3 new investments per year. 
 
The firm is focused on therapeutics but is modality and indication agnostic. This includes orphan diseases. Platform or multi-asset companies are often valued over single asset opportunities. Preferred stage of development varies based on the validation level of both the therapeutic target(s) and technology being applied. The more validated the targets and/or technology, the earlier the firm’s investor group is able to invest, including specific investment cases prior to pre-clinical animal efficacy. 
 
The firm does not have specific management team requirements and has taken board seats in the past, however it is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2020 and headquartered in the US participates in Pre-Seed and Seed stage funding rounds to tech and science focused companies. The firm typically allocates $1M USD per company and will either lead or participate in a syndicate, though they prefer to lead. The firm invests globally. 
 
The firm invests in a wide range of sectors including, but not limited to, energy, robotics, life sciences, software services, education, and more. In terms of life sciences and healthcare, the firm is also agnostic and will look at therapeutics, medical devices, diagnostics, and digital health. If looking at medical devices, the firm prefers them to be AI and/or robotics driven. The firm does not look at single assets and rather prefers platform or technology driven assets. The firm is also indication-agnostic. Companies should be in development stages. 
 
The firm requires a full-time team. The firm also will take a board observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm headquartered in Taiwan is firm overall is focused on investing in biotech and tech-related companies such as AI, biotech, medical device, pharma, fintech, semiconductors, smart manufacturing, etc. The firm is stage agnostic, however, within life science and healthcare, the firm is also focusing on early-stage companies from Pre-Series A to Series B. Typical check sizes range from $1M-10M, although usually it will be $3M-5M to start. The firm participates in co-investing, but 60-70% of the time, the firm will lead. The firm is looking at companies in the U.S., Japan, Taiwan, and Central Eastern Europe, with the goal of creating a cross-border ecosystem that helps healthcare and biotech companies thrive. The firm is also willing to help later-stage companies with commercialization and connect with Taiwanese partners and key players in the U.S. 
 
The firm invests in fundamental science driven companies with a technology focus. The main sectors the company focuses on is chronic disease management/treatment, AI and/or digital health, and service-based companies. Main indication areas include oncology, metabolic diseases, and autoimmune diseases, however indication areas are not limited to those listed. The firm is also open to orphan diseases, however, it has to be a platform that addresses orphan diseases to validate the technology. The firm looks at in-development and clinical stages as well as pre-approval, but they may not be interested in very early stages. For drugs, the firm requires proof of biology with an established animal model data. 
 
The firm may invest in young teams to grow with them, however most of the time, the firm prefers companies to have an experienced team in place. The firm also requires taking a board seat, if not, at least an observer seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm based in Europe is solely focused on life sciences. The firm had a recent close on their fourth fund and is actively looking for new investments, usually in Series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America with more of a focus on the U.S. 
 
The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is not evaluating diagnostic technologies for the current fund. The firm is generally agnostic in terms of subsectors and indications with the primary focus on products that address clear unmet opportunities. Historically, the firm has invested in biotech therapeutics that address a wide variety of inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases. 
 
The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2018 with offices in US and Asia. The firm invests in mainly Seed and Series A rounds, however, the firm is not stage-focused or valuation sensitive as their core focus is in return opportunities. The firm has around a 70-person global investment team that focuses on healthcare, consumer, enterprise, frontier, fintech, and more. The firm invests globally, acting as a co-investor, making about 2-5 new portfolio investments each quarter and about 2-5 follow-on investments each quarter. Initial check sizes go up to $1M USD. 
 
As the firm is a generalist fund in terms of healthcare, the firm is looking for transformative technologies that shape the future. 
 
The firm values the founder’s vision to solve the most painful problems from the root cause with cost-effective solutions that can benefit large populations.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A healthcare-dedicated venture capital fund with offices in US and Europe is managed by a team of seasoned venture managers and entrepreneurs. The fund will make early-stage equity investments in preclinical and clinical-stage drug development companies. The investment size of the fund will range between USD 5-30 million per company. The fund prefers to invest in European-based companies, but exceptional opportunities in the US will also be considered. The fund has had its first closing and is actively seeking new investment opportunities. 
 
The firm is seeking to invest in innovative drug development companies. The fund has a special interest in biologics and is open to all indications including orphan indications. Generics, reformulations or second-use products (“micro-innovation”) are not part of the investment strategy. 
 
The firm is looking for companies with a strong and qualified management team or technical experts in the relevant technology.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.